What were the key takeaways from Skye Bioscience's earnings call?

What is Skye Bioscience's gross profit margin?

Did Skye Bioscience beat or miss consensus estimates last quarter?

What factors drove the changes in Skye Bioscience's revenue and profit?

What is Skye Bioscience's latest dividend and current dividend yield?

What guidance did Skye Bioscience's management provide for the next earnings period?

What were the key takeaways from Skye Bioscience’s earnings call?

What is the market's earnings forecast for Skye Bioscience next quarter?

- **Higher Dose Expansion**: Initiated 400mg/600mg IV cohorts to confirm PK/safety, with subcutaneous delivery via ENHANZE for Phase IIb.
- **Combination Efficacy**: 22.3% weight loss at 52 weeks vs. 6.3% for monlunabant, with no neuropsychiatric risk.
- **APC Innovation**: Unimolecular construct achieves 3-day dosing equivalence to daily combo, preserving orthogonal mechanisms.
- **Phase IIb Focus**: GLP-1 experienced patients with plateaued weight loss, targeting Q4 2026 data readout.

**【CEO Opening Remarks】**
- Skye Bioscience reported progress in the CB1 antagonist program, nimacimab, highlighting its potential as an add-on therapy for GLP-1 experienced patients.
- The CBeyond study demonstrated a 22.3% mean weight loss at 52 weeks with nimacimab + semaglutide, with no neuropsychiatric safety signals.
- Expansion of the CBeyond study to evaluate higher doses (400mg/600mg IV) to confirm PK and safety, with plans to transition to subcutaneous delivery using Halozyme's ENHANZE technology.

**【CEO & CTO Clinical Update】**
- Monotherapy at 200mg weekly underexposed peripheral tissues; translational data suggest 600mg weekly may achieve full CB1 inhibition in adipose/liver.
- Off-treatment follow-up showed nimacimab + semaglutide maintained fat mass loss (17.8% weight regain vs. 38.7% for semaglutide alone), supporting durability.
- FDA feedback supports Phase IIb design as add-on therapy, focusing on GLP-1 experienced patients with plateaued weight loss.

**【APC Program Update】**
- Introduced antibody-peptide conjugate (APC) combining nimacimab with GLP-1 receptor agonist, achieving equivalent efficacy to daily combination therapy with 3-day dosing.
- APC program demonstrates potential to simplify administration while preserving orthogonal mechanisms.

**【Q&A Highlights】**
- Dose selection rationale: 400mg/600mg IV based on PK modeling showing 7x IC90 serum levels vs. 20mg monlunabant (6.3% weight loss vs. 1.5% for nimacimab).
- ENHANZE formulation expected for Phase IIb; auto-injector for Phase III.
- APC program viewed as long-term optionality, not near-term value driver.
- Phase IIb timeline: Final protocol by Q4 2026, enrollment start in 2027.

Skye Bioscience, Inc.(SKYE)-20260311-2025 Q4 Earnings call transcript

- **Phase IIa Results Stand Out**: Nimasimab + semaglutide delivered 3% additional weight loss (p=0.0372) with no safety issues.
- **Durability Advantage**: 18% weight regain vs. 50% for semaglutide alone, supporting maintenance potential.
- **Higher Doses Key**: PK/PD modeling shows efficacy improves with exposure; Phase IIb combo study to define optimal dose.
- **CMC Progress**: Scalable manufacturing and cost optimization on track for commercial readiness.
- **Positive KOL Feedback**: Physicians highlight nimasimab's differentiated mechanism and safety profile.

**【CFO Financial Commentary】**
- Cash and cash equivalents: $35.3 million, providing runway into 2027 for Phase IIa extension and manufacturing activities.
- R&D expenses: $9.4 million (Q3 2025) vs. $4.9 million (Q3 2024), driven by clinical trial costs, contract manufacturing, and discovery R&D.
- G&A expenses: $3.9 million (Q3 2025) vs. $4.6 million (Q3 2024), down due to reduced consulting fees and recruitment costs.
- Net loss: $12.8 million (Q3 2025), including $1.9 million in share-based compensation.

**【CEO Clinical Update and Strategy】**
- **Phase IIa CB1 Study Results**: Nimasimab + semaglutide achieved 3% additional weight loss (p=0.0372) vs. semaglutide alone, with no neuropsychiatric or additive GI adverse events.
- **Body Composition Benefits**: Improved lean-to-fat mass ratio (0.26 vs. 0.13, p=0.0126) and reduced waist circumference (3.17 cm, p=0.0492).
- **Durability**: 18% weight regain (2.3 kg) vs. 50% (4.7 kg) for semaglutide alone (p=0.006).
- **Extension Study**: 43 patients enrolled (300 mg monotherapy, 200 mg combo), with data expected Q1-Q2 2026.
- **CMC Progress**: High-concentration formulations on track, cost optimization efforts underway.
- **R&D Validation**: Preclinical data confirms nimasimab's fat-selective mechanism and durability.

**【Q&A Highlights】**
- **Dose-Response Relationship**: Higher doses correlate with greater efficacy; Phase IIb combo study to evaluate optimal dose.
- **Extension Study Sample Size**: 43 patients sufficient for PK/PD modeling, not powered for statistical significance.
- **Regulatory Path**: Potential for monotherapy and maintenance approvals; discussions with agencies ongoing.
- **Rebound Data**: Nimasimab's durability differentiates it from GLP-1s, with 18% regain vs. 50% for semaglutide.
- **Safety Concerns**: No CNS adverse events observed; GI tolerability comparable to placebo.
- **KOL Feedback**: Enthusiasm for nimasimab's safety profile and potential in maintenance therapy.

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

- **Clinical Momentum**: Phase IIa CBeyond study on track for late Q3/early Q4 2025 readout, with preclinical data showing nimacimab's potential as a combination therapy (44% weight loss vs. 29.7% for tirzepatide alone) and maintenance therapy (7.4% weight regain vs. 29.7% for GLP-1s).
- **Financial Strength**: $48.6 million cash runway supports operations through Q1 2027, with strategic investments in CMC and clinical operations.
- **Differentiated Profile**: Nimacimab's peripheral CB1 inhibition addresses GLP-1 limitations (high discontinuation rates, GI side effects), with potential for monotherapy, combination, and maintenance use cases.
- **Upcoming Catalysts**: KOL event on September 4, 2025, and Phase I NAFLD data at EASD on September 19, 2025, ahead of top-line CBeyond data in Q4 2025.

**【CEO Summary Section】**
- **Phase IIa Clinical Progress**: Nimacimab's Phase IIa CBeyond study completed enrollment ahead of schedule, with 26-week patient visits projected to conclude shortly. The Data Safety Monitoring Committee (DSMC) has reviewed the study 4 times without recommending changes. Top-line data expected in late Q3/early Q4 2025.
- **Mechanism of Action**: Nimacimab is a peripherally restricted CB1 antibody with negligible brain penetration, offering a broader therapeutic window. It binds allosterically, maintaining efficacy even in high endocannabinoid states, unlike small molecule CB1 inhibitors.
- **Preclinical Data Highlights**: 
  - Combination with suboptimal tirzepatide (3 nm/kg) achieved 44% vehicle-adjusted weight loss vs. 29.7% for tirzepatide alone.
  - Nimacimab demonstrated durable weight loss post-treatment, with 7.4% regain by day 24 vs. 29.7% for low-dose tirzepatide.
  - Maintenance therapy reduced rebound weight gain from 29.7% to 12.8% when added after low-dose tirzepatide.
- **Market Positioning**: Nimacimab targets gaps in GLP-1 therapies, including high discontinuation rates (50% within 1 year), lean mass loss, and GI side effects. Potential use cases include monotherapy, combination therapy, and maintenance therapy.

**【CFO Financial Commentary】**
- **Cash Position**: $48.6 million as of Q2 2025, sufficient to fund operations and clinical milestones through Q1 2027.
- **R&D Expenses**: $14.3 million in Q2 2025 (vs. $4.1 million in Q2 2024), driven by contract manufacturing, clinical trial costs, and discovery research.
- **G&A Expenses**: $3.9 million in Q2 2025 (vs. $4.3 million in Q2 2024), reflecting team expansion (20 employees) and strategic hires in regulatory affairs, CMC, and clinical operations.
- **Upcoming Milestones**: 
  - KOL event on September 4, 2025, to discuss mechanism, clinical data, and market positioning.
  - Phase I SAD/MAD NAFLD data presentation at EASD on September 19, 2025.
  - Top-line CBeyond data in late Q3/early Q4 2025.

**【Q&A Key Highlights】**
- **R&D Costs and Arecor Partnership**: $9.1 million of Q2 R&D expenses allocated to contract manufacturing. Arecor collaboration aims to increase nimacimab concentration (targeting 200 mg/mL) for less frequent dosing, with no impact on clinical development timelines.
- **CBeyond Efficacy Expectations**: Study powered to detect 8% placebo-adjusted weight loss. 5%-8% range considered compelling, with focus on safety, tolerability, and biomarkers (e.g., GLP-1, leptin).
- **Discontinuation Rates**: ~25%-30% in Phase IIa, consistent with industry norms. Nimacimab's peripheral mechanism and lack of neuropsychiatric side effects position it as a complementary maintenance therapy (50% of patients discontinue GLP-1s after 1 year).
- **Extension Study Enrollment**: ~50% of original CBeyond patients eligible for 26-week extension, with optimism for high participation rates. Data from 13-week post-treatment follow-up expected in H1 2026.

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

- **Phase 2a Trial Extended to 52 Weeks**: Nimacimab monotherapy shows 23.5% weight loss in preclinical models, combination with tirzepatide achieves 31.5%.
- **Differentiated Mechanism**: Allosteric CB1 inhibition avoids CNS exposure, maintaining efficacy across physiological states.
- **Financial Stability**: $59.2M cash runway supports operations through Q1 2027.
- **Regulatory Readiness**: FDA interactions planned post-Q3 2025 data release to discuss Phase 2b design.
- **Commercial Potential**: $1B+ opportunities for both monotherapy and combination therapies.

**【CEO Summary Section】**
- Completed enrollment in Phase 2a CBeyond Trial ahead of schedule, extended to 52 weeks for longer-term safety and efficacy data.
- Generated preclinical data showing nimacimab achieves 23.5% weight loss as monotherapy and 31.5% in combination with tirzepatide in DIO models.
- Highlighted nimacimab's differentiated mechanism as a peripherally restricted CB1 inhibitor with no CNS penetration.
- Addressed regulatory uncertainty, noting nimacimab's clinical development milestones are unaffected by policy shifts.

**【CSO Preclinical Data】**
- Nimacimab demonstrated 23.5% weight loss in DIO models, comparable to small molecule CB1 inhibitors but with preserved lean mass.
- Combination with tirzepatide achieved 31.5% weight loss, driven by additive effects on caloric intake and peripheral pathways.
- Allosteric binding mechanism avoids competition with endocannabinoids, maintaining potency regardless of physiological conditions.
- Independent lab validation confirmed reproducibility of weight loss and biomarker changes (fasting insulin, GLP-1).

**【CFO Financial Update】**
- Cash balance of $59.2M as of Q1 2025, sufficient to fund operations through Q1 2027.
- R&D expenses $7.2M (vs. $1.9M YoY), driven by Phase 2a clinical trial costs.
- G&A expenses $4.6M (vs. $4.2M YoY), due to investor relations and marketing.
- Net loss $11.1M, including $2.2M non-cash share-based compensation.
- Tariff risk mitigation: European manufacturing partner unaffected; US-based drug product production stable.

**【Q&A Key Takeaways】**
- FDA interactions planned post-Q3 2025 top-line data release to discuss Phase 2b dose-ranging study design.
- Combination therapy potential validated by preclinical data, targeting patients unresponsive to GLP-1 agonists.
- Regulatory strategy focuses on nimacimab as monotherapy with combination studies to follow.
- No neuropsychiatric AEs reported in DMC reviews; safety profile remains strong.
- Commercial opportunity estimated at billions for both monotherapy and combination, with equal magnitude.

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

- **CBeyond Trial Success**: 136 patients enrolled (13% over target), with 52-week data expected in Q2 2026.
- **Safety Profile**: No neuropsychiatric AEs in Phase I; DSMB reviews confirm safety.
- **Financial Strength**: $68.4M cash balance, supporting operations through Q1 2027.
- **Differentiation**: Nimacimab's peripheral CB1 inhibition avoids CNS risks seen in small molecules.
- **Pipeline Focus**: Resources shifted to nimacimab, with potential expansion into diabetes.

**【CEO Summary Section】**
- Completed enrollment of 136 patients in the CBeyond trial, exceeding the original target of 120 patients.
- Nimacimab manufacturing transferred to a partner, with GMP runs initiated for scale-up.
- Phase IIa DSMB reviews confirmed no safety concerns, with a third review scheduled for April 2025.
- Extended trial to 52 weeks, with full data expected in Q2 2026, potentially 3 months earlier than prior guidance.
- Preclinical data shows nimacimab drives weight loss in diet-induced obesity models without CNS penetration.
- Discontinued SBI 100 development to focus resources on nimacimab.

**【CFO Financial Commentary】**
- 2024 R&D expenses: $18.7M (vs. $5.8M in 2023), driven by clinical and manufacturing costs for nimacimab.
- 2024 GAAP net loss: $26.6M, with $8.3M non-cash share-based compensation.
- Cash balance as of Dec 31, 2024: $68.4M, supporting operations through at least Q1 2027.
- Q4 2024 operating cash burn: $8.1M, expected to maintain similar levels in 2025.
- Eliminated related-party balances and resolved litigation matters, freeing up restricted cash.

**【Q&A Key Points】**
- **Enrollment & Safety**: Rapid enrollment driven by investigator enthusiasm and nimacimab's differentiated mechanism. DSMB reviews confirmed no safety issues, with no neuropsychiatric AEs reported in Phase I.
- **Data Timing**: 26-week top-line data expected late Q3/early Q4 2025, 52-week data in Q2 2026. Extended trial eliminates interim analysis, preserving statistical power.
- **Preclinical Insights**: Nimacimab's peripheral CB1 inhibition impacts multiple metabolic pathways, with no CNS penetration observed.
- **Market Context**: Non-GLP-1 mechanisms gaining traction, with nimacimab positioned as a safer alternative to small molecule CB1 inhibitors.
- **Future Plans**: Phase IIb design discussions with regulators, manufacturing optimization for commercial readiness, and exploration of diabetes indications.


Actual	-0.2	-0.1	-0.24	-0.28	-0.44	-0.32	-0.36
Forecast	-0.195	-0.2494	-0.2784	-0.287	-0.32	-0.3138	-0.2971
Surprise	-2.56%	+59.90%	+13.79%	+2.44%	-37.50%	-1.98%	-21.17%

Actual	0	0	0	0	0	0	0
Forecast	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

SKYE

SKYE fundamentals

SKYE Q4 2025 Earnings

Earnings Call

You can ask Aime

SKYE

SKYE fundamentals

SKYE Q4 2025 Earnings

Earnings Call

SKYE Earnings Call Summary for Q4/20254:30 PM on Mar 10, 2026

SKYE Earnings Call Summary for Q3/20254:30 PM on Nov 10, 2025

SKYE Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

SKYE Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

SKYE Earnings Call Summary for Q4/20244:30 PM on Mar 20, 2025

You can ask Aime